You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Find out information about our rare diseases products, including prescribing and safety information.

Products in our rare diseases portfolio:

  • Strimvelis (Autologous CD34+ enriched cell fraction transduced to encode for human adenosine deaminase (ADA).

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Strimvelis is a registered trademark of the GlaxoSmithKline group of companies